Columbia cancer researchers are investigating how exercise, early puberty, and hormones may play a role in the rising numbers of early onset breast cancer.
In the same way that ChatGPT understands human language, a new AI model developed by Columbia computational biologists captures the language of cells to accurately predict their activities.
By generating movies of individual molecules performing actions that make our bodies tick, Columbia researchers have a deeper understanding of a process important in cancer and other diseases.
Columbia’s Dian Yang is placing CRISPR-based molecular recorders into cancer cells to eavesdrop on cancer evolution and pinpoint when and how cells metastasize.
Human embryos often fail to cope with high levels of replication stress early in development. Their failure not only impairs fertility treatment but may have long-ranging impacts on our health.
PARP inhibitors have improved survival of breast cancer patients with BRCA1/2 mutations, but the cancer eventually returns. A Columbia study has now identified a drug that may prevent that relapse.
Four Columbia researchers were awarded pilot grants—made possible by proceeds from Velocity, Columbia’s annual cycling fundraiser—to support their early-stage cancer research.
Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.